1-Oxo-2-carbamoyl-3-aethyl-inden | 93001-66-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 1-Oxo-2-carbamoyl-3-aethyl-inden
• 英文别名: 1-Ethyl-3-oxoindene-2-carboxamide
• CAS: 93001-66-2
• 化学式: C₁₂H₁₁NO₂
• 分子量: 201.225
• InChiKey: XLJKNYWLMKVQLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  60.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(1-苯基亚丙基)丙二腈 在 硫酸 作用下， 以21%的产率得到(1Z)-1-ethylidene-3-oxoindene-2-carboxamide
  参考文献：
  名称：

  1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase

  摘要：

  Fibroblast growth factor receptor (FGFr) mediated signal transduction is implicated in vascular proliferative diseases and some cancers. We have identified methyl 1-oxo-3-phenyl-1H-indene-2-carboxylic ester as a small molecule inhibitor of the tyrosine kinase activity of FGFr-1, (IC50 = 5.1 mu M). We report here the synthesis and structure-activity studies about this template core. Additionally, screening of this series against a panel of tyrosine kinases shows selective inhibition of FGFr. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10110-x

文献信息

• [EN] DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE MODULATION DE LA DIFFERENCIATION ET UTILISATIONS ASSOCIEES
  申请人：UNIV QUEENSLAND

  公开号：WO2005065686A1

  公开（公告）日：2005-07-21

  This invention discloses methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signalling pathway, especially the FGF-1 or FGF-2 signalling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma and lipomatosis.

  该发明揭示了调节前脂肪细胞分化潜能和/或增殖的方法和药剂。更具体地，本发明揭示了调节成纤维细胞生长因子（FGF）信号通路的方法和药剂，特别是FGF-1或FGF-2信号通路，用于治疗或预防与脂肪相关的疾病，包括但不限于肥胖、脂肪瘤和脂肪增生。
• Differentiation modulating agents and uses therefor
  申请人：Prins Bernhard Johannes

  公开号：US20050282733A1

  公开（公告）日：2005-12-22

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR
  申请人：Prins Johannes Bernhard

  公开号：US20120059047A1

  公开（公告）日：2012-03-08

  The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• 1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase
  作者：M.R. Barvian、R.L. Panek、G.H. Lu、A.J. Kraker、A. Amar、B. Hartl、J.M. Hamby、H.D.H. Showalter

  DOI：10.1016/s0960-894x(97)10110-x

  日期：1997.11

  Fibroblast growth factor receptor (FGFr) mediated signal transduction is implicated in vascular proliferative diseases and some cancers. We have identified methyl 1-oxo-3-phenyl-1H-indene-2-carboxylic ester as a small molecule inhibitor of the tyrosine kinase activity of FGFr-1, (IC50 = 5.1 mu M). We report here the synthesis and structure-activity studies about this template core. Additionally, screening of this series against a panel of tyrosine kinases shows selective inhibition of FGFr. (C) 1997 Elsevier Science Ltd.